Circular 14 October 2024: Ethionamide Availability and Therapeutic Alternative
The Paediatric Hospital Level Standard Treatment Guidelines (STGs) and Essential Medicines List (EML) recommends the use of ethionamide in the regimens for the management of miliary tuberculosis (TB), and TB meningitis (TBM). The available stock of ethionamide expired on 1 October 2024, and currently there is no other stock in the country to service this clinical need. The sourcing of ethionamide
The Paediatric Hospital Level Standard Treatment Guidelines (STGs) and Essential Medicines List (EML) recommends the use of ethionamide in the regimens for the management of miliary tuberculosis (TB), and TB meningitis (TBM).
The available stock of ethionamide expired on 1 October 2024, and currently there is no other stock in the country to service this clinical need. The sourcing of ethionamide stock is currently underway, and supply is expected to resume in December 2024. Updates on availability and timelines will be shared as they become available.